The DOI matches its Crossref record.
EHT0202 in Alzheimers Disease: A 3-Month, Randomized, Placebo- Controlled, Double-Blind Study
Abstract
BACKGROUND: EHT0202 (etazolate hydrochloride) is a new compound exhibiting both potential disease-modifying and symptomatic treatment properties in Alzheimer's Disease increasing alpha-secretase activity and sAPP alpha secretion, as well as acting as a GABA-A receptor modulator and as a PDE-4 inhibitor. METHODS: This pilot, randomized, double-blind, placebo-controlled, parallel group, multicentre, Phase IIA study was conducted in 159 randomized patients suffering from mild to moderate Alzheimer's Disease. EHT0202 (40 or 80 mg bid) or placebo was administered as adjunctive therapy to one acetylcholinesterase inhibitor over a 3-month period. This study was designed to assess the clinical safety and tolerability of EHT0202 as a primary objective, with secondary endpoints (cognitive function, daily living activities, behaviour, caregiver burden and global functioning) included to explore clinical efficacy of EHT0202 versus placebo. RESULTS: EHT0202 was shown to be safe and generally well tolerated. Dose-dependent numbers of early withdrawal and central nervous system related adverse events were observed. As expected, since the study was not powered and not designed to show drug efficacy, and except for ratings on the ADCS-ADL scale, no significant differences were seen between treatment groups. CONCLUSIONS: These first encouraging safety results do support further development of EHT0202 in order to assess its clinical efficacy and to confirm its tolerability in a larger cohort of Alzheimer patients and for a longer period.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Etazolate (EHT0202) is listed as another α-secretase modulators which acts as a selective GABA receptor modulator. The agent was reported to have a safety profile with a good tolerance in AD patients (Vellas et al., 2011).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Vellas et al., 2011
In the citing paper
“A previous, phase 2 trial has showed that the agent was safe and well tolerated in patients with mild to moderate AD.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [48]
In the citing paper
“Etazolate (EHT0202) stimulates the nonamyloidogenic α-secretase pathway acting as a selective modulator of GABA receptors.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [48]
In the citing paper
“However, further evaluation of etazolate in phase 3 trials has not progressed.48”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [48]
In the citing paper
“Restricted, nowadays, knowledge assumes that α-secretase activation is promoted through the phosphatidylinositol 3-kinase (PI3K)/Akt pathway and may be through γ-aminobutyric acid (GABA) receptor signaling; thus, agents that activate the PI3K/Akt pathway or act as selective GABA receptor modulators are suggested as potential therapeutic drugs for AD.47,48”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [48]
Citations
Cited by
Sorted by citations
Items 101–133 of 133
Alzheimer’s Disease: Evolving Therapeutics, Scientific Progress, and Key Challenges
Sai Yasasvi, K., Goswami, A. K., Prasad, M. R., Chauhan, V. S., & Yadav, N. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02468 · Cited by 4
Calciano, M. A., Lemarié, J. C., Blondiaux, E., Einstein, R., & Fehlbaum, P. (2013) · Biomarkers · doi:10.3109/1354750x.2013.773083 · Cited by 4
Self-citationTo Target or Not to Target Schistosoma mansoni Cyclic Nucleotide Phosphodiesterase 4A?
Zheng, Y., Schroeder, S., Kanev, G. K., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076817 · Cited by 4
Abo‐Neima, S. E., El-Sheekh, M. M., & Keshk, R. M. (2023) · BioNanoScience · doi:10.1007/s12668-023-01199-7 · Cited by 4
Passive immunotherapy - a viable treatment for Alzheimer's disease.
Yi, K. (2014) · PubMed · Cited by 4
Khalaf, H. S., El-Sayed, A. F., & Shamroukh, A. H. (2025) · RSC Advances · doi:10.1039/d5ra07372c · Cited by 3
Shah, F. A., Qadir, H., Khan, J., & Faheem, M. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.03.064 · Cited by 3
Efficacy of medications in controlling cognitive dysfunction in Alzheimer’s : a systematic review
de Andrade, S. M., Rodrigues, Í. S. M., Rosa, L. M. V., Taminato, R. L., & dos Santos, G. A. A. (2025) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2024-0243 · Cited by 4
Jiang, X., Wang, W., Liu, Z., et al. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13033 · Cited by 3
Alzheimer Hastalığı Tedavisindeki Güncel Yaklaşımlar
ODABAŞI, M. D., & KÜÇÜKKILINÇ, Z. T. T. (2021) · Hacettepe University Journal of the Faculty of Pharmacy · doi:10.52794/hujpharm.955421 · Cited by 6
Therapeutics of Alzheimer’s Disease
Herrera-Rivero, M., & Emiliano, G. (2011) · InTech eBooks · doi:10.5772/27990 · Cited by 3
Salehinejad, M. A., & Jouzdani, A. F. (2026) · Brain Network Disorders · doi:10.1016/j.bnd.2026.01.002 · Cited by 2
Assessment of the genotoxicity and cytotoxicity of etazolate in cultured human lymphocytes
Halabi, Y. Z. A., Khabour, O. F., & Alzoubi, K. H. (2022) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2022.121013 · Cited by 2
“A pilot phase IIA, randomized, double-blind, multicenter clinical trial that included 159 patients with Alzheimer’s disease demonstrated the safety and tolerability of etazolate and its ability to alter disease progression (Vellas et al., 2011).”
Thérapeutiques en regard des anomalies physiopathologiques de la maladie d’Alzheimer
Delrieu, J., Piau, A., & Vellas, B. J. (2011) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2011.03.005 · Cited by 1
Self-citationAdvances in the treatment of Alzheimer’s disease
Goceroglu, R. T., & Hacımüftüoğlu, A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1819165 · Cited by 1
“A Phase II trial involving patients with AD found that the agent was safe and well-tolerated (Vellas et al., 2011).”
The Drug Development Based on Pathogenetic Research in Alzheimer’s Disease
Lin, X., & Zhang, Q. (2014) · Advances in Alzheimer s Disease · doi:10.4236/aad.2014.32007 · Cited by 1
Pathophysiology and Management Approaches in Alzheimer’s Disease
Jain, S., Goel, D., Nazir, S. S., Yadav, V., & Vohora, D. (2023) · Springer eBooks · doi:10.1007/978-981-99-6807-7_4 · Cited by 2
Chiu, S. (2017) · International Journal of Complementary & Alternative Medicine · doi:10.15406/ijcam.2017.06.00203 · Cited by 2
Recent Update of Clinical Drug Trials in Alzheimer’s Disease
Kang, H., & Park, K. W. (2015) · Journal of the Korean Neurological Association · doi:10.17340/jkna.2015.4.2
Future Pharmacological Armamentaria in Management of Alzheimer Disease
Shah, M. H., Shah, H. D., & Chaudhari, V. (2013) · DOAJ (DOAJ: Directory of Open Access Journals)
Kilimann, I., Grothe, M. J., Thyrian, J. R., & Teipel, S. J. (2016) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-016-1588-9
“Nachdem es gehäu© zu aseptischen Meningoenzephalitiden kam (6 % aller Teilnehmer in der Behandlungsgruppe), wurde die Studie vorzeitig beendet.”
BackgroundInfluentialINIBIDORES DAS FOSFODIESTERASES DOS NUCLEÓTIDOS CÍCLICOS NA TERAPÊUTICA FARMACOLÓGICA
Morgado, S., Morgado, M., & Costa, I. M. (2015) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.25756/rpf.v4i2.71
Substanz(en) Firma/Institution Studienname Phase/Status Teilnehmer (Anzahl) Ergebnisse Referenzen
Janssen, B., Lilly, S. E., & Uni, W. (2016)
Pharmacological interventions in mild cognitive impairment and dementia
Hugon, J., & Paquet, C. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198701590.003.0128
Antiamyloid therapy of Alzheimer’s disease: origins, current state and prospects of development
Vorobev, S. V., Emelin, А. Y., Yanishevskij, S. N., Kostina, E. V., & Galaeva, A. A. (2022) · Neurology Bulletin · doi:10.17816/nb108278
Amyloid β hypothesis in the development of therapeutic agents for Alzheimer's disease
Adeniji, A. O., Johnson, C., & Mody, V. V. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30008-0.00020-x
Receptor targets in Alzheimer's disease drug discovery
Stanley, B., Wallach, J. V., & Adejare, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30008-0.00013-2
Emerging therapeutics and future insights into the pathobiology of Alzheimer’s disease
Ullah, S.-K. L. I. (2018) · International Journal of Biosciences (IJB) · doi:10.12692/ijb/12.2.231-246
Alzheimer Hastalığı Tedavisindeki Güncel Yaklaşımlar
ODABAŞI, M. D., & KÜÇÜKKILINÇ, Z. T. T. (2021) · DergiPark (Istanbul University)
Marqueurs périphériques de l'inflammation et déclin cognitif au cours de la maladie d'Alzheimer
Julian, A. (2018) · theses.fr (ABES) · doi:10.70675/0f58e0a1z28d9z40b7z886fz752caf42c261
Fereidouni, A., Nematollahi, S., Mathew, K. T., Favennec, V., Liceran, L., Aldenhoff-Kelly, C., Valdivieso, M. A., Trent, S., & Moradikor, N. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.154063 · Cited by 1
Kim, H. J., Kim, J.-H., Son, Y., Kim, J., & Hong, J. H. (2026) · Antioxidants · doi:10.3390/antiox15091195
Metadata
- Authors
- Vellas, B., Sol, O., J. Snyder, P., Ousset, P.-J., Haddad, R., Maurin, M., Lemarie, J.-C., Desire, L., & P. Pando, M.
- Affiliations
- Inserm (FR)
- Venue
- Current Alzheimer Research
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2011-03-01
- Volume
- 8
- Issue
- 2
- Pages
- 203-212
- ISSN
- 1567-2050 (ISSN-L)
- OpenAlex
- W2101276626
- Cited by
- 133
- References
- 0
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 7 · 2023: 5 · 2022: 13 · 2021: 10 · 2020: 11 · 2019: 6 · 2018: 11 · 2017: 11 · 2016: 7 · 2015: 5 · 2014: 12 · 2013: 10 · 2012: 8
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- Current Alzheimer Research (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, alpha-secretase, GABA-A receptor modulation, adjunctive therapy, acetylcholinesterase inhibitors, drug safety and tolerability, cognitive function, activities of daily living, behavior, caregiver burden, clinical efficacy
- MeSH terms
- Aged, Alzheimer Disease, Double-Blind Method, Etazolate, Female, Humans, Male, Phosphodiesterase Inhibitors, Pilot Projects, Time Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
